Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 57.90 INR
Change Today +0.50 / 0.87%
Volume 2.7M
As of 7:06 AM 04/30/15 All times are local (Market data is delayed by at least 15 minutes).

marksans pharma ltd (MRKS) Snapshot

Open
57.00
Previous Close
57.40
Day High
59.00
Day Low
56.15
52 Week High
04/15/15 - 75.10
52 Week Low
06/4/14 - 20.10
Market Cap
23.7B
Average Volume 10 Days
4.1M
EPS TTM
1.87
Shares Outstanding
409.3M
EX-Date
09/18/14
P/E TM
31.0x
Dividend
0.10
Dividend Yield
0.17%
Current Stock Chart for MARKSANS PHARMA LTD (MRKS)

Related News

No related news articles were found.

marksans pharma ltd (MRKS) Related Businessweek News

No Related Businessweek News Found

marksans pharma ltd (MRKS) Details

Marksans Pharma Limited, together with its subsidiaries, is engaged in the research, manufacture, and marketing of generic pharmaceutical formulations worldwide. Its product portfolio covers primary therapeutic segments of CVS, analgesics, decongestants, gastrointestinal, cardiovascular, anti-diabetics, central nervous system, oncology, anti-allergic drugs, and others. It also manufactures and distributes over-the-counter pharmaceutical products in the areas of cough and cold remedies, galenicals, vitamins, palliative and healthcare items, oils, antiseptics, and disinfectants; and offers contract research and manufacturing services to global pharmaceutical companies. Marksans Pharma Limited is headquartered in Mumbai, India.

596 Employees
Last Reported Date: 03/27/15

marksans pharma ltd (MRKS) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

marksans pharma ltd (MRKS) Key Developments

Marksans Pharma Ltd. Reports Standalone and Consolidated Earnings Results for the Nine Months Ended December 31, 2014

Marksans Pharma Ltd. reported standalone and consolidated earnings results for the nine months ended December 31, 2014. For the period, on standalone basis, the company reported total revenues were INR 3,138,554,711, profit before exceptional and extraordinary items and tax was INR 797,944,532, profit before tax was INR 797,944,532 and profit for the period after adjustments for minority interest was INR 548,040,360. For the period, on consolidated basis, the company reported total revenues were INR 6,262,683,915, profit before exceptional and extraordinary items and tax was INR 1,195,774,155, profit before tax was INR 1,195,774,155, profit for the period after adjustments for minority interest was INR 843,488,457, net cash used in operating activities of INR 803,858,253 and purchase of business/fixed assets was INR 319,140,085.

Marksans Pharma Ltd. Reports Unaudited Standalone and Consolidated Earnings Results for the Third Quarter and Nine Months Ended December 31, 2014

Marksans Pharma Ltd. reported unaudited standalone and consolidated earnings results for the third quarter and nine months ended December 31, 2014. For the quarter, on standalone basis, net sales /income from operations was INR 1,058.40 million compared to INR 807.4 million a year ago. Profit from operations before other income finance cost and exceptional items was INR 334.15 million compared to INR 198.54 million a year ago. Profit from ordinary activities before tax was INR 280.88 million against INR 181.83 million a year ago. Net profit was INR 165.19 million or INR 0.43 per basic and diluted share before and after extraordinary items compared to INR 156.84 million or INR 0.41 per basic and diluted share before and after extraordinary items a year ago. For the nine months, on standalone basis, net sales /income from operations was INR 3,138.55 million compared to INR 2,312.74 million a year ago. Profit from operations before other income finance cost and exceptional items was INR 914.07 million compared to INR 668.58 million a year ago. Profit from ordinary activities before tax was INR 797.94 million against INR 551.18 million a year ago. Net profit was INR 548.04 million or INR 1.42 per basic and diluted share before and after extraordinary items compared to INR 502.68 million or INR 1.30 per basic and diluted share before and after extraordinary items a year ago. EBITDA was INR 980.2 million against INR 735.5 million a year ago. For the quarter, on consolidated basis, the company reported net sales /income from operations was INR 2,132.94 million compared to INR 1,687.49 million a year ago. Profit from operations before other income finance cost and exceptional items was INR 484.90 million compared to INR 298.03 million a year ago. Profit from ordinary activities before tax was INR 421.49 million against INR 269.65 million a year ago. Net profit was INR 284.34 million or INR 0.72 per basic and diluted share after extraordinary items compared to INR 229.92 million or INR 0.58 per basic and diluted share after extraordinary items a year ago. For the nine months, on consolidated basis, net sales /income from operations was INR 6,281.63 million compared to INR 4,711.34 million a year ago. Profit from operations before other income finance cost and exceptional items was INR 1,342.43 million compared to INR 848.67 million a year ago. Profit from ordinary activities before tax was INR 1,195.77 million against INR 694.43 million a year ago. Net profit was INR 860.10 million or INR 2.19 per basic and diluted share after extraordinary items compared to INR 626.87 million or INR 1.59 per basic and diluted share after extraordinary items a year ago. EBITDA increased 50.80% at INR 1,462.2 million against INR 969.6 million a year ago.

Marksans Pharma Ltd., Board Meeting, Feb 07, 2015

Marksans Pharma Ltd., Board Meeting, Feb 07, 2015. Agenda: To consider and approve unaudited financial results for the quarter ended 31st December, 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MRKS:IN 57.90 INR +0.50

MRKS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MRKS.
View Industry Companies
 

Industry Analysis

MRKS

Industry Average

Valuation MRKS Industry Range
Price/Earnings 23.3x
Price/Sales 2.8x
Price/Book 10.1x
Price/Cash Flow 21.3x
TEV/Sales 2.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MARKSANS PHARMA LTD, please visit www.marksanspharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.